Phase 1: the revolution is ongoing!
A revolution is ongoing, which has already changed and will continue to change the role of phase 1 studies in oncology drug development.
Exhibitor & Support Opportunities
Act now to identify the best strategies at TAT 2017 to ensure maximum results for your company in this dynamic marketplace.
Registration will open September 1, 2016
Abstract submission will open September 1, 2016.
TAT 2016 report
A brief report of TAT 2016 is online now. Over the three days of the conference, 45 oral presentations covered 23 unique new drugs or drug classes in early-phase clinical trials at the time of the conference.